Neurogenesis and Peptides: Can New Brain Cells Be Stimulated?
Neurotrophic Peptides
80%
Increase in newborn neurons in the dentate gyrus of TBI mice treated with Peptide 6, a CNTF-derived peptide.
Chohan et al., Neurosurgery, 2015
Chohan et al., Neurosurgery, 2015
View as imageFor decades, the adult human brain was considered a finished product, incapable of generating new neurons. That assumption collapsed in the late 1990s when researchers confirmed that the hippocampus, the brain region critical for learning and memory, continues to produce new neurons throughout life.[1] This process, called neurogenesis, declines sharply with age and deteriorates further in neurodegenerative diseases like Alzheimer's. A growing body of preclinical research now suggests that specific peptides can reverse some of that decline, stimulating progenitor cell proliferation, protecting newborn neurons from apoptosis, and improving memory in animal models. The evidence is almost entirely from rodent studies, but the results are striking enough to warrant close attention. For a broader look at how peptides support the brain, see our pillar article on BDNF, the brain peptide that builds new neural connections.
Key Takeaways
- Peptide 6, derived from ciliary neurotrophic factor (CNTF), increased newborn neurons in the dentate gyrus by 80% in a mouse model of traumatic brain injury (Chohan et al., 2015)
- Cerebrolysin rescued impaired neurogenesis in Alzheimer's transgenic mice by reducing apoptosis of neural progenitor cells, not by increasing proliferation (Rockenstein et al., 2007)
- A single intranasal dose of Semax produced a 1.4-fold increase in BDNF protein and a 3-fold increase in BDNF mRNA in the rat hippocampus (Dolotov et al., 2006)
- Ghrelin knockout mice showed reduced hippocampal progenitor cells and impaired memory, both of which were restored by ghrelin replacement (Li et al., 2013)
- The tripeptide KED (Lys-Glu-Asp) regulated expression of neuronal differentiation genes nestin and GAP43 in cell models of Alzheimer's disease (Khavinson et al., 2021)
- No human randomized controlled trials have specifically tested whether any peptide increases neurogenesis in the living human brain
What Is Neurogenesis and Why Does It Matter?
Neurogenesis refers to the birth of new neurons from neural stem and progenitor cells. In the adult mammalian brain, this process occurs primarily in two regions: the subgranular zone (SGZ) of the hippocampal dentate gyrus and the subventricular zone (SVZ) lining the lateral ventricles.[1] The hippocampal site matters most for cognition because newborn granule cells integrate into existing circuits that encode spatial memory, pattern separation, and emotional regulation.
Neurogenesis declines with age across species. In mouse models of Alzheimer's disease, the decline is steeper and correlates with cognitive deficits.[2] This has made neurogenesis an attractive therapeutic target: if you could restore the production of new neurons to youthful levels, you might slow or partially reverse memory loss. Neurotrophic factors like BDNF and NGF naturally support this process, which is why researchers have turned to peptides that either mimic these factors or stimulate their release. For a deeper look at those growth factors, see our article on neurotrophic peptides and brain health.
CNTF-Derived Peptides: Peptide 6 and P21
Ciliary neurotrophic factor (CNTF) is a protein that supports neuron survival, but its large size and inability to cross the blood-brain barrier make it impractical as a drug. Researchers at the New York State Institute for Basic Research solved this by designing small peptides based on CNTF's active region.
Peptide 6
Peptide 6 is an 11-amino-acid peptide that crosses the blood-brain barrier, has a plasma half-life exceeding 6 hours, and works by competitively inhibiting leukemia inhibitory factor (LIF) signaling.[1] In a 2011 study, 30 days of subcutaneous Peptide 6 treatment in normal adult C57BL/6 mice increased the proliferation and survival of neural progenitor cells in the dentate gyrus, boosted MAP2 and synaptophysin immunoreactivity (markers of dendritic and synaptic density), and improved reference memory on the Morris water maze.[1]
The same group then tested Peptide 6 in a controlled cortical impact model of mild to moderate traumatic brain injury. TBI mice treated with 50 nmol/day of Peptide 6 for 30 days showed an 80% increase in newborn neurons (but not uncommitted progenitor cells) in the dentate gyrus compared to saline controls.[3] The peptide also reversed TBI-induced dendritic and synaptic density loss, increased activity in tri-synaptic hippocampal circuitry, and improved memory recall on behavioral testing. Critically, it reduced Alzheimer-type hyperphosphorylated tau and amyloid-beta levels that appeared after TBI.[3]
P21: A Modified CNTF Peptide
P21 (Ac-DGGLAG-NH2) takes a different approach. This hexapeptide incorporates an adamantane moiety to improve metabolic stability.[4] When administered peripherally to normal adult mice, P21 enhanced both short-term and spatial reference memory while increasing neurogenesis and maturation of newly born neurons in the dentate gyrus granular cell layer and subgranular zone.[4] The fact that P21 works in normal mice (not just disease models) raises questions about whether CNTF-derived peptides could enhance cognition beyond baseline, though this remains untested in humans.
Both Peptide 6 and P21 represent a broader strategy covered in our article on how peptides modulate neuroplasticity.
Cerebrolysin: A Peptide Mixture That Rescues Neural Progenitors
Cerebrolysin is a mixture of low-molecular-weight neuropeptides derived from porcine brain tissue. It contains active fragments resembling BDNF, NGF, GDNF, and CNTF, and has been used clinically in Europe and Asia for stroke and dementia. Its effects on neurogenesis have been studied in multiple Alzheimer's transgenic mouse models.
Rescuing Impaired Neurogenesis
In 2007, Rockenstein and colleagues showed that APP transgenic mice had decreased numbers of BrdU-positive and doublecortin-positive (DCX+) neural progenitor cells in the SGZ compared to controls.[2] Cerebrolysin treatment for 1 and 3 months significantly increased BrdU+ cells and DCX+ neuroblasts while decreasing TUNEL+ and activated caspase-3 immunoreactive progenitor cells. The mechanism was protective rather than proliferative: cerebrolysin did not increase PCNA+ (proliferating) cells or change the ratio of neurons to astroglia among newborn cells.[2] It rescued neurogenesis by keeping progenitor cells alive, not by making them divide faster.
Regional Differences
A 2011 comparison of cerebrolysin versus CNTF-derived peptides found that both increased neuroblast counts across the SVZ, olfactory bulb, and hippocampus in APP transgenic mice, but through different mechanisms.[5] Cerebrolysin reduced apoptosis (decreased TUNEL staining) without altering PCNA levels, while Peptides 6 and 6A increased PCNA+ cell counts, indicating enhanced proliferation. This distinction matters: anti-apoptotic and pro-proliferative approaches could theoretically be combined for additive effects, though no study has tested this.
Supporting Stem Cell Grafts
In a 2015 study, cerebrolysin treatment enhanced the survival of murine neural stem cells grafted into the hippocampus of APP transgenic mice over 9 months.[6] The surviving grafted cells showed reduced caspase-3 activation and increased BDNF and furin immunoreactivity. Most surviving cells remained as neuroblasts rather than maturing into fully integrated neurons, raising questions about the functional significance of graft survival alone. For a detailed look at cerebrolysin's mechanisms, see how cerebrolysin works as a neurotrophic factor.
Semax and the BDNF/trkB Pathway
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of ACTH(4-10) developed in Russia. It crosses the blood-brain barrier after intranasal administration and has documented effects on learning and neuroprotection. Its neurogenic potential appears to operate through BDNF upregulation rather than direct action on neural progenitor cells.
A 2006 study by Dolotov and colleagues found that a single intranasal dose of Semax (50 microg/kg) produced a maximal 1.4-fold increase in BDNF protein levels in the rat hippocampus, accompanied by a 1.6-fold increase in trkB tyrosine phosphorylation (indicating receptor activation).[7] At the mRNA level, the effects were even larger: a 3-fold increase in exon III BDNF mRNA and a 2-fold increase in trkB mRNA. Semax-treated animals showed more conditioned avoidance reactions, a measure of learning.[7]
BDNF is one of the strongest known promoters of adult hippocampal neurogenesis. By upregulating BDNF and activating its receptor, Semax likely promotes neurogenesis indirectly, though no study has directly quantified new neuron counts after Semax treatment. This is a gap worth noting: the BDNF connection is well-established, but the neurogenesis link remains inferential. For more on how BDNF supports new neural connections, see the BDNF pillar article.
Ghrelin: The Hunger Hormone That Grows Neurons
Ghrelin, the 28-amino-acid peptide hormone released by the stomach during fasting, is primarily known for stimulating appetite. But ghrelin receptors (GHS-R1a) are expressed throughout the hippocampus, and a series of studies has shown that ghrelin directly promotes adult hippocampal neurogenesis independent of the growth hormone/IGF-1 axis.
Direct Evidence from Knockout Mice
Li and colleagues (2013) used ghrelin knockout (GKO) mice to test whether endogenous ghrelin is necessary for normal neurogenesis.[8] Targeted deletion of the ghrelin gene resulted in reduced numbers of progenitor cells in the SGZ, decreased BrdU-positive cells, fewer immature neurons, and fewer newly generated mature neurons. GKO mice also showed impaired performance on Y-maze and novel object recognition tests. Ghrelin replacement restored progenitor cell numbers to wild-type levels and rescued the memory deficits.[8]
The Caloric Restriction Connection
A 2019 review in Trends in Endocrinology and Metabolism synthesized evidence linking ghrelin, caloric restriction, and neurogenesis.[9] Caloric restriction has long been known to enhance hippocampal neurogenesis in rodents, and ghrelin (which rises during food restriction) appears to be a key mediator. This provides a potential molecular explanation for the cognitive benefits of intermittent fasting observed in animal studies: food restriction raises ghrelin, ghrelin stimulates hippocampal progenitor proliferation and differentiation, and new neurons integrate into memory circuits.[9]
The clinical implications remain speculative. Ghrelin agonists exist (MK-677, for example, is a ghrelin receptor agonist), but none have been tested for neurogenesis-specific outcomes in humans. Whether pharmacologically elevated ghrelin replicates the neurogenic effects of caloric restriction-induced ghrelin release is unknown.
Short Peptides and Bioregulators
Not all neurogenic peptides are synthetic drugs or hormones. Two lines of research point to simpler molecules with surprising effects.
KED: A Three-Amino-Acid Bioregulator
KED (Lys-Glu-Asp) is a tripeptide studied primarily by Russian researchers in the Khavinson bioregulator tradition. Oral KED improved memory and attention in elderly individuals with functional CNS disorders in early clinical observations.[10] In cell models of Alzheimer's disease, KED regulated the expression of neuronal differentiation genes (NES and GAP43) and the proteins they encode (nestin and GAP43), as well as cell aging genes p16 and p21 and AD-associated genes SUMO, APOE, and IGF1.[10]
The KED data is intriguing but preliminary. Gene expression changes in cell culture do not prove that new neurons are born in a living brain. The clinical observations in elderly patients lacked placebo controls. This peptide illustrates a pattern common across the field: promising molecular signals that have not yet been validated in rigorous in vivo neurogenesis studies.
Collagen Peptides
In a 2012 study, oral administration of low-molecular-weight collagen peptides (below 2,000 Da) for 4 weeks increased the density of proliferating cells in the hippocampal subgranular zone by 1.2-fold compared to higher-molecular-weight collagen peptides in C57BL/6 mice.[11] The low-molecular-weight group also spent less time in closed arms on the elevated plus maze, suggesting reduced anxiety. The mechanism linking orally consumed collagen fragments to hippocampal cell proliferation remains unexplained. The authors did not identify which specific collagen-derived peptides reached the brain or through what receptor pathway they acted.
How Far Are These Therapies From the Clinic?
The honest answer: far. Every neurogenesis study described in this article was conducted in rodents, with one exception (the preliminary KED observations in elderly humans, which lacked controlled design). Several obstacles stand between these findings and approved treatments.
Measuring neurogenesis in living humans is extremely difficult. Unlike in mice, where BrdU labeling and immunohistochemistry on brain sections quantify newborn neurons directly, human neurogenesis studies rely on indirect measures: postmortem tissue, carbon-14 birth-dating, or MRI proxies that lack the resolution to count individual new neurons. Even whether adult hippocampal neurogenesis occurs at meaningful rates in humans remains debated, with conflicting reports from different laboratories.
Animal model translation is unreliable for brain disorders. Many compounds that enhance neurogenesis in APP transgenic mice have failed to show cognitive benefits in human Alzheimer's trials. The transgenic models overexpress single mutant proteins, while human neurodegeneration involves decades of multi-factorial pathology.
The functional significance of new neurons is unclear. Increasing the number of BrdU+ or DCX+ cells does not guarantee those cells will mature, integrate into existing circuits, and improve cognition. The cerebrolysin graft study found most surviving transplanted cells remained as neuroblasts rather than mature neurons.[6]
That said, the convergence of multiple peptide classes (CNTF-derived, neurotrophic mixtures, ACTH analogs, gut hormones) all pointing toward hippocampal neurogenesis suggests this is a real biological pathway, not an artifact of one model system. The challenge is moving from "peptide X increases BrdU+ cells in mice" to "peptide X produces measurable cognitive benefit in humans through verified neurogenesis." No peptide has completed that journey yet.
For related research on how peptides interact with neural circuits, see how peptides modulate neuroplasticity and nerve growth factor (NGF), the original neurotrophic peptide. The Dihexa story also intersects with neurogenesis research through its hepatocyte growth factor mechanism.
The Bottom Line
Multiple peptide classes promote hippocampal neurogenesis in animal models through distinct mechanisms: CNTF-derived peptides increase progenitor proliferation, cerebrolysin protects progenitor cells from apoptosis, Semax upregulates BDNF signaling, and ghrelin directly stimulates neural stem cell differentiation. All major evidence comes from rodent studies. No human trial has yet demonstrated that a peptide can increase neurogenesis in the living human brain, and measuring that outcome remains a fundamental technical barrier.